Shandong Xinhua Pharmaceutical Company Limited（0719.HK）股价、财务与研究

盘中时间采用HKT。市场数据可能有所延迟。

公司概况

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.

行业: Medical - Pharmaceuticals
部门: Healthcare
总部: CN
首席执行官: Wen Hui Xu
上市以来: 2000年1月4日
雇员: 7,240

市场位置

成交量: 15.2万; 0.1× 平均值
平均成交量: 152.94万; 日均成交量
市值: 86.93亿 HKD
贝塔: -0.03; 市场参考 1

财务数据

财务快照

估值与收益率

企业价值: 39.97亿 CNY
EV/EBITDA: 4.04×
盈利收益率: 7.10%
自由现金流收益率: 10.24%

盈利能力和效率

净资产收益率: 5.56%
资产收益率: 3.15%
投入资本回报率: 4.03%

财务健康

流动比率: 1.43×
奥特曼 Z 分数: 2.92
皮奥特罗斯基 F 分数: 7 共 9 个

财务报表

利润率趋势

盈利能力占已公布营收的百分比。

毛利率营业利润率净利润率

损益趋势

营收

87.55亿 CNY+3.41%

营业利润

3.64亿 CNY-31.89%

净利润

2.9亿 CNY-38.32%

项目（CNY）	2025财年	2024财年	2023财年	2022财年	2021财年
营收	87.55亿 CNY	84.66亿 CNY	81.01亿 CNY	75.03亿 CNY	65.6亿 CNY
销货成本	71.1亿 CNY	64.25亿 CNY	57.79亿 CNY	54.66亿 CNY	47.86亿 CNY
毛利	16.45亿 CNY	20.42亿 CNY	23.21亿 CNY	20.37亿 CNY	17.74亿 CNY
研究与开发	4.4亿 CNY	4.13亿 CNY	4.19亿 CNY	3.46亿 CNY	3.41亿 CNY
销售、一般及管理费用	3.41亿 CNY	6.08亿 CNY	12.98亿 CNY	8.15亿 CNY	6.89亿 CNY
营业费用	12.28亿 CNY	15.07亿 CNY	17.87亿 CNY	14.94亿 CNY	12.75亿 CNY
利息收入	748.65万 CNY	1112.55万 CNY	937.68万 CNY	1046.2万 CNY	877.63万 CNY
利息支出	4333.2万 CNY	3973.93万 CNY	4114.86万 CNY	4970.69万 CNY	5310.34万 CNY
折旧和摊销	5.88亿 CNY	5.41亿 CNY	5.17亿 CNY	4.85亿 CNY	4.34亿 CNY
营业利润	3.64亿 CNY	5.34亿 CNY	5.35亿 CNY	4.77亿 CNY	4.26亿 CNY
净利润	2.9亿 CNY	4.7亿 CNY	4.97亿 CNY	4.11亿 CNY	3.49亿 CNY